공시 • Apr 23
Natera, Inc. Features Prospera Evidence In Heart And Lung Transplantation Across 17 Presentations at ISHLT
Natera, Inc. announced a broad body of evidence supporting its Prospera test at the 2026 International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting. Prospera will be featured in 17 abstracts, including six oral presentations. Together with academic colleagues, Natera will highlight Prospera’s expanding clinical utility in heart and lung transplantation, spanning rejection surveillance, imaging correlation, and real-world clinical decision-making. Key highlights include: In heart transplant: Prospera Heart serial dynamics (increases/decreases) predicted a variety of adverse outcomes at 1-year post-transplant, in addition to rejection. Patients with a positive Prospera result were up to 4x more likely to experience adverse outcomes by 1-year post-transplant – including graft dysfunction, rejection, hospitalization, or death – and Prospera outperformed biopsy in detecting many of these outcomes. (ProTECT study and DEFINE-HT study) Real-world clinical impact: in more than 30% of cases, Prospera results influenced physician decisions related to immunosuppression or biopsy, demonstrating clinical utility beyond just identifying acute rejection. (ProTECT study) New independent validation solidifies the excellent performance of Prospera Heart with DQS, preserving high sensitivity while reducing false positives by 30% compared to donor fraction alone. (TRIFECTA-Heart study) In lung transplant: Data from multiple abstracts highlight the ability of Prospera Lung to detect infection, chronic lung allograft dysfunction (CLAD), and early signs of graft damage, including scenarios where such complications were undetected on biopsy. (Abstracts # 1158 and 401) While the standard cutoff for a Prospera-positive result is 1%, many studies have shown that significantly increased Prospera results (>2%), defined as extreme molecular injury (EMI), convey even higher risk of CLAD and mortality. New data suggests that a preemptive treatment approach to identify EMI can lead to improved patient outcomes, including forced expiratory volume in 1 second (FEV1). (Abstract #1152) Prospera Lung was able to detect gastroesophageal reflux, showing a 77% quantitative decrease after treatment with antireflux surgery, and demonstrating the utility of Prospera as a biomarker for lung allograft injury caused by reflux and microaspiration in addition to rejection. (Abstract #1147) The full list of presentations at ISHLT includes: April 22, 6:00 PM ET | Abstract #764 Presenter: Amir Emtiazjoo, M.D., MSc Lung Transplantation Outcomes in Patients with Respiratory Failure Related to BIPF Following Treatment for Malignancy April 23, 4:30 PM ET | Abstract #902 Presenter: Shelley Hall, M.D. Association of Donor Derived-Cell Free DNA with 1-Year Outcomes in Heart Transplant Recipients: Findings from the ProTECT Study April 23, 4:30 PM ET | Abstract #867 Presenter: Brent C. Lampert, D.O. dd-cfDNA Informs Clinical Decision-Making in Heart Transplantation: Insights from the ProTECT Study April 23, 4:30 PM ET | Abstract #868 Presenter: Palak Shah, M.D., M.S. A Randomized Study of Rejection Surveillance with dd-cfDNA versus Endomyocardial Biopsy (ACES-EMB) April 23, 4:30 PM ET | Abstract #921 Data from the Trifecta-Heart Study Presenter: Martina Mackova, Ph.D. Assessing Early Antibody-Mediated Rejection (AMR) Using MMDx, dd-cfDNA, and Histology April 23, 4:30 PM ET | Abstract #916 Presenter: Roopa A. Rao, M.D. Trend of Donor-Derived Cell-Free DNA and DNA Quantity Score in Response to Rejection Treatment in Heart Transplant Recipients April 23, 4:30 PM ET | Abstract #1001 Presenter: Paul J. Kim, M.D., MAS Dissecting Clinically Discordant dd-cfDNA Elevations After Heart Transplantation: Insights from the DEFINE-HT Study April 23, 4:30 PM ET | Abstract #1158 Presenter: Ambalavanan Arunachalam, M.D., M.S. Donor-Derived Cell-Free DNA Predicts Abnormal Findings on Chest Computed Tomography (CT) Imaging Post-Lung Transplantation April 23, 4:30 PM ET | Abstract #1157 Presenter: Selim M. Arcasoy, M.D., MPH dd-cfDNA May Be Discordant with Cellular Profiles in BALF After Lung Transplantation (LT): A LAMBDA Study Analysis April 23, 4:30 PM ET | Abstract #1152 Presenter: Chang (Jason) Li, M.D. Preemptive Treatment of 'Molecular Injury' Assessed by Donor-Derived Cell-Free DNA After Lung Transplant April 23, 4:30 PM ET | Abstract #1147 Presenter: Samir Sultan, D.O., M.S. Lung Allograft Injury Improves After Gastroesophageal Reflux Surgery According to Donor-Derived Cell-Free DNA April 24, 10:00 AM ET | Abstract #150 (Oral Presentation) Presenter: Attila Feher, M.D., Ph.D., Correlation Between Donor Derived Cell Free DNA and Cardiac Allograft Vasculopathy Detected by PET Myocardial Perfusion Imaging: Minidepict Study April 24, 4:30 PM ET | Abstract #401 (Mini Oral Presentation) Presenter: Majd Alkhouri, M.D. Donor-Derived Cell-Free DNA for Detection of Infection and Rejection After Lung Transplantation April 24, 4:30 PM ET | Abstract #402 (Mini Oral Presentation) Presenter: Eric Morrell, M.D. Distinct Alveolar and Plasma Molecular Injury Profiles Between Acute Allograft Injuries April 24, 4:30 PM ET | Abstract #420 (Mini Oral Presentation) Data from the Trifecta-Heart Study Presenter: Phillip F. Halloran, M.D., Ph.D. Validation of a Two-Threshold Algorithm (2TA) Combining dd-cfDNA Fraction and Quantity to Detect Heart Transplant Rejection April 24, 4:30 PM ET | Abstract #424 (Mini Oral Presentation) Data from the Trifecta-Heart Study Presenter: Katelynn S. Madill-Thomsen, Ph.D. Molecular Microscope® (MMDx) and dd-cfDNA versus Histology for the Diagnosis of Heart Allograft Rejection April 24, 4:30 PM ET | Abstract #425 (Mini Oral Presentation) Data from the ProTECT Study Presenter: Roopa A. Rao, M.D. Outcomes in Heart Transplant Recipients with Extreme Elevations in Donor Derived Cell-Free DNA %.
